V

    Verastem Inc (VSTM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.22
    +0.00 (+0.00%)

    Market Cap: $653.87M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    48%(19/40)
    Avg Surprise
    -5.72%
    Streak
    5 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.43
    Range$-0.44 - $-0.42
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.37+13.2%
    60d ago$-0.37+13.2%
    30d ago$-0.37+13.2%
    7d ago$-0.37+13.2%
    Current$-0.43
    Revenue Consensus
    $29M
    Range$27M - $31M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.46
    Range$-0.46 - $-0.46
    1 analysts
    Revenue Consensus
    $43M
    Range$29M - $52M
    9 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.46---
    Sep 26EST
    		-$-0.43---
    Jun 26
    Reported Aug 6
    		$-0.35$-0.46+23.91%Beat+10.3%
    Mar 26
    Reported May 7
    		$-0.43$-0.47+8.51%Beat+45.6%
    Dec 25
    Reported Mar 4
    		$-0.46$-0.50+7.55%Beat+23.5%
    Sep 25
    Reported Nov 4
    		$-0.54$-0.61+11.48%Beat+38.6%
    Jun 25
    Reported Aug 7
    		$-0.39$-0.59+33.90%Beat+36.1%
    Mar 25
    Reported May 13
    		$-0.79$-0.77-2.60%Miss+19.4%
    Dec 24
    Reported Mar 20
    		$-0.60$-0.74+18.56%Beat+41.2%
    Sep 24
    Reported Nov 6
    		$-0.88$-0.82-7.32%Miss-23.9%
    Jun 24
    Reported Aug 8
    		$-0.61$-1.06+42.45%Beat+47.0%
    Mar 24
    Reported May 9
    		$-0.98$-0.87-12.64%Miss+14.0%
    Dec 23
    Reported Mar 14
    		$-1.02$-0.62-64.52%Miss-1175.0%
    Sep 23
    Reported Nov 8
    		$-0.71$-0.79+10.13%Beat+34.3%
    Jun 23
    Reported Aug 8
    		$-1.15$-1.02-12.75%Miss+20.1%
    Mar 23
    Reported May 9
    		$-1.14$-0.98-16.33%Miss-5.6%
    Dec 22
    Reported Mar 14
    		$-0.08$-0.10+20.00%Beat+11.1%
    Sep 22
    Reported Nov 3
    		$-1.08$-1.47+26.53%Beat+30.8%
    Jun 22
    Reported Aug 8
    		$-1.44$-1.32-9.09%Miss-20.0%
    Mar 22
    Reported May 9
    		$-1.08$-1.02-5.88%Miss+0.0%
    Dec 21
    Reported Mar 28
    		$-0.09$-0.09+0.00%Beat+25.0%
    Sep 21
    Reported Nov 4
    		$-1.56$-0.84-85.71%Miss-262.5%
    Jun 21
    Reported Aug 2
    		$-1.20$-1.00-20.00%Miss+28.6%
    Mar 21
    Reported May 11
    		$-1.08$-1.08+0.00%Beat+74.3%
    Dec 20
    Reported Mar 18
    		$-0.12$-0.08-50.00%Miss+76.5%
    Sep 20
    Reported Nov 9
    		$0.96$0.52+84.62%Beat+122.9%
    Jun 20
    Reported Aug 10
    		$-1.68$-1.76+4.55%Beat+70.8%
    Mar 20
    Reported May 7
    		$-4.20$-2.58-62.79%Miss+32.7%
    Dec 19
    Reported Mar 11
    		$-0.51$-0.45-13.33%Miss-4.1%
    Sep 19
    Reported Oct 29
    		$-4.20$-4.92+14.63%Beat+29.6%
    Jun 19
    Reported Aug 1
    		$-5.76$-5.84+1.37%Beat-3.6%
    Mar 19
    Reported May 9
    		$-6.24$-5.64-10.64%Miss-1422.0%
    Dec 18
    Reported Mar 12
    		$-0.49$-0.53+7.55%Beat+90.5%
    Sep 18
    Reported Nov 7
    		$-5.97$-4.68-27.56%Miss+18.4%
    Jun 18
    Reported Aug 8
    		$-5.56$-4.30-29.30%Miss-28.7%
    Mar 18
    Reported May 3
    		$-0.41$-0.39-5.13%Miss+90.2%
    Dec 17
    Reported Mar 13
    		$-5.16$-5.10-1.18%Miss-1512.5%
    Sep 17
    Reported Nov 7
    		$-7.32$-3.96-84.85%Miss-190.5%
    Jun 17
    Reported Aug 8
    		$-4.32$-3.96-9.09%Miss-
    Mar 17
    Reported May 10
    		$-4.20$-4.32+2.78%Beat-
    Dec 16
    Reported Mar 23
    		$-0.32$-0.25-28.00%Miss-
    Sep 16
    Reported Nov 7
    		$-2.52$-2.85+11.58%Beat-

    Key Metrics

    Valuation
    P/E Ratio-4.06EV/EBITDA-0.19x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-231.60%Operating Margin-81.60%
    ROE-471.20%ROIC-158.74%
    Financial Health
    Debt/Equity1.58xInterest Coverage-138.95x
    Current Ratio2.25xQuick Ratio2.22x
    Trading Statistics
    Beta0.29Avg Volume1.84M
    52-Week High$11.2552-Week Low$3.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.16
    SMA 20$6.86
    SMA 50$5.85
    SMA 200$6.26
    EMA 10$7.11
    EMA 20$6.84
    EMA 50$6.16
    EMA 200$6.05

    MACD

    Line: 0.39Signal: 0.41Hist: -0.03

    ADX

    ADX: 40.3+DI: 31.4-DI: 18.8

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down16.0
    PSAR$7.86

    Bollinger Bands

    Upper Band$7.85
    Lower Band$5.87
    %B Position2883%(Upper)
    Band Width0.68

    RSI (14-Day)

    Neutral
    61.9

    Momentum Oscillators

    Stoch %K59.4
    Stoch %D64.7
    Williams %R-45.1
    ROC (10d)0.6%
    Momentum0.04
    CCI (20d)61.2
    MFI (14d)57.7

    Volatility Measures

    ATR (14d)$0.42(5.8%)
    StdDev (20d)0.49
    Hist Vol71.1%(High)

    Volume Flow

    VWAP$7.18
    OBV22.1M
    AD Line-42.8M
    CMF (20d)0.122

    Volume Metrics

    Avg Vol (20d)1.9M
    Vol Ratio0.7x
    VWMA (20d)$6.85

    Pivot Points

    R3$7.54
    R2$7.46
    R1$7.34
    Pivot Point$7.26
    S1$7.14
    S2$7.06
    S3$6.94

    Advanced Oscillators

    TSI27.47
    Ultimate Osc57.7
    KST274.50

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$40.08M$18.67M$17.54M$11.24M$2.14M$0$-9,976,000$0$10.00M$0$114,000$0
    Cost of Revenue$3.76M$2.77M$2.61M$1.67M$318,000$0$12,000$0$0$0$5,000$0
    Gross Profit$36.32M$15.90M$14.92M$9.57M$1.82M$0$-9,988,000$0$10.00M$0$109,000$0
    Operating Expenses$69.03M$60.80M$56.40M$50.29M$45.58M$44.17M$31.59M$37.03M$28.28M$28.06M$31.14M$21.31M
    R&D$41.34M$38.22M$31.67M$28.99M$24.79M$29.15M$20.81M$24.75M$18.06M$17.71M$22.50M$13.95M
    SG&A$27.41M$22.30M$24.45M$21.01M$20.67M$15.02M$10.78M$12.28M$10.21M$10.35M$8.64M$7.36M
    Operating Income$-32,710,000$-44,897,000$-41,476,000$-40,715,000$-43,764,000$-44,174,000$-31,590,000$-37,030,000$-18,277,000$-28,059,000$-31,139,000$-21,309,000
    Interest Income$1.11M$1.30M$1.10M$1.18M$822,000$960,000$968,000$831,000$983,000$1.37M$1.87M$2.25M
    Interest Expense$360,000$382,000$415,000$319,000$212,000$2.02M$1.15M$1.15M$1.14M$1.13M$1.12M$1.13M
    Income Before Tax$-33,857,000$-36,591,000$-209,471,000$0$-25,934,000$-52,063,000$-130,452,000$0$0$0$-27,701,000$-20,191,000
    Income Tax Expense$816,000$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-34,673,000$-36,591,000$-32,916,000$-98,518,000$-25,934,000$-52,103,000$-64,551,000$-23,967,000$-8,256,000$-33,863,000$-27,368,000$-20,004,000
    EBITDA$-34,441,000$-37,346,000$-33,307,000$-99,089,000$-26,417,000$-50,965,000$-69,985,000$-23,442,000$-8,089,000$-28,502,000$-29,282,000$-21,675,000
    EBIT$-34,605,000$-37,506,000$-33,605,000$-99,381,000$-26,544,000$-51,005,000$-70,199,000$-23,650,000$-8,101,000$-28,089,000$-28,450,000$-21,309,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VSTM

    News

    Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views

    Analysts have lowered the average assessed fair value for Verastem (VSTM) from $16.13 to $14.75, primarily due to a more cautious outlook on competition and revenue assumptions. Despite these cuts, some analysts maintain bullish ratings, citing confidence in pipeline execution and upcoming catalysts. However, others express concern about increasing competition and the need for stronger differentiation, leading to varied price target revisions.

    Yahoo Finance•8/25/26•
    Somewhat-Bearish

    VSTM: Upcoming KRAS G12D Data Readout Will Drive The Next Repricing

    Analysts have adjusted their average price target for Verastem (VSTM) from $16.13 to $14.75, reflecting updated Q2 models and more conservative revenue growth assumptions, though many maintain a positive outlook. The company recently dosed the first patient in its TARGET-D 203 Phase 2 trial for KRAS G12D mutated metastatic colorectal cancer and reported encouraging preliminary data from the TARGET-D 101 Phase 1/2 trial. Upcoming clinical data for VS-7375 in October is seen as a significant catalyst that could influence investor perception of Verastem's growth potential and risk profile.

    Simply Wall Street•8/25/26•
    Neutral

    Enterprise value to revenue forward of Verastem, Inc. – NASDAQ:VSTM

    This article provides a brief financial overview of Verastem, Inc. (NASDAQ: VSTM), focusing on its enterprise value to revenue forward metric. It displays key financial data points such as period, value, change, and percentage change. The content appears to be a snapshot from a financial data platform.

    TradingView•8/23/26•
    Neutral

    VSTM | Verastem, Inc. Financials - Revenue Breakdown

    This article provides a detailed financial breakdown for Verastem, Inc. (VSTM), focusing on revenue, insider trading, institutional holdings, and government contracts. It also includes information on the company's U.S. patents, executive compensation, and analyst ratings, while highlighting the absence of specific segment or geographical revenue data. The platform, Quiver Quantitative, offers various tools for financial analysis, including backtesting strategies and tracking politician stock portfolios.

    Quiver Quantitative•8/18/26•
    Neutral

    Precision Trading with Verastem Inc. (VSTM) Risk Zones

    This article from Stock Traders Daily provides a detailed analysis of Verastem Inc. (VSTM), highlighting strong near and mid-term sentiment but a weak long-term outlook. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, with defined entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths and support/resistance levels generated by AI models.

    Stock Traders Daily•8/16/26•
    Bullish

    Frequently Asked Questions About VSTM

    Does VSTM pay dividends?
    Verastem Inc (VSTM) does not currently pay a regular dividend.
    What is VSTM's market cap?
    Verastem Inc (VSTM) has a market capitalization of $653.87M with a current stock price of $7.22.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In